244 related articles for article (PubMed ID: 24292634)
1. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice.
Di Marco E; Gray SP; Chew P; Koulis C; Ziegler A; Szyndralewiez C; Touyz RM; Schmidt HH; Cooper ME; Slattery R; Jandeleit-Dahm KA
Diabetologia; 2014 Mar; 57(3):633-42. PubMed ID: 24292634
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/- mice.
Di Marco E; Gray SP; Chew P; Kennedy K; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Clin Sci (Lond); 2016 Aug; 130(15):1363-74. PubMed ID: 27190136
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis.
Manea SA; Vlad ML; Fenyo IM; Lazar AG; Raicu M; Muresian H; Simionescu M; Manea A
Redox Biol; 2020 Jan; 28():101338. PubMed ID: 31634818
[TBL] [Abstract][Full Text] [Related]
4. Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling.
Gray SP; Di Marco E; Kennedy K; Chew P; Okabe J; El-Osta A; Calkin AC; Biessen EA; Touyz RM; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):295-307. PubMed ID: 26715682
[TBL] [Abstract][Full Text] [Related]
5. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice.
Judkins CP; Diep H; Broughton BR; Mast AE; Hooker EU; Miller AA; Selemidis S; Dusting GJ; Sobey CG; Drummond GR
Am J Physiol Heart Circ Physiol; 2010 Jan; 298(1):H24-32. PubMed ID: 19837950
[TBL] [Abstract][Full Text] [Related]
6. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lewis P; Stefanovic N; Pete J; Calkin AC; Giunti S; Thallas-Bonke V; Jandeleit-Dahm KA; Allen TJ; Kola I; Cooper ME; de Haan JB
Circulation; 2007 Apr; 115(16):2178-87. PubMed ID: 17420349
[TBL] [Abstract][Full Text] [Related]
7. Endothelium-restricted endothelin-1 overexpression in type 1 diabetes worsens atherosclerosis and immune cell infiltration via NOX1.
Ouerd S; Idris-Khodja N; Trindade M; Ferreira NS; Berillo O; Coelho SC; Neves MF; Jandeleit-Dahm KA; Paradis P; Schiffrin EL
Cardiovasc Res; 2021 Mar; 117(4):1144-1153. PubMed ID: 32533834
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina.
Deliyanti D; Wilkinson-Berka JL
J Neuroinflammation; 2015 Jul; 12():136. PubMed ID: 26219952
[TBL] [Abstract][Full Text] [Related]
9. PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice.
Kong L; Shen X; Lin L; Leitges M; Rosario R; Zou YS; Yan SF
Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1779-87. PubMed ID: 23766264
[TBL] [Abstract][Full Text] [Related]
10. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
Jha JC; Gray SP; Barit D; Okabe J; El-Osta A; Namikoshi T; Thallas-Bonke V; Wingler K; Szyndralewiez C; Heitz F; Touyz RM; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
J Am Soc Nephrol; 2014 Jun; 25(6):1237-54. PubMed ID: 24511132
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic mice.
Zetterqvist AV; Berglund LM; Blanco F; Garcia-Vaz E; Wigren M; Dunér P; Andersson AM; To F; Spegel P; Nilsson J; Bengtsson E; Gomez MF
PLoS One; 2014; 8(6):e65020. PubMed ID: 23755169
[TBL] [Abstract][Full Text] [Related]
12. Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse.
Chew P; Yuen DY; Koh P; Stefanovic N; Febbraio MA; Kola I; Cooper ME; de Haan JB
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):823-30. PubMed ID: 19325139
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial dysfunction and metabolic reprogramming induce macrophage pro-inflammatory phenotype switch and atherosclerosis progression in aging.
Vendrov AE; Lozhkin A; Hayami T; Levin J; Silveira Fernandes Chamon J; Abdel-Latif A; Runge MS; Madamanchi NR
Front Immunol; 2024; 15():1410832. PubMed ID: 38975335
[TBL] [Abstract][Full Text] [Related]
14. NOXA1-dependent NADPH oxidase regulates redox signaling and phenotype of vascular smooth muscle cell during atherogenesis.
Vendrov AE; Sumida A; Canugovi C; Lozhkin A; Hayami T; Madamanchi NR; Runge MS
Redox Biol; 2019 Feb; 21():101063. PubMed ID: 30576919
[TBL] [Abstract][Full Text] [Related]
15. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.
Gorin Y; Cavaglieri RC; Khazim K; Lee DY; Bruno F; Thakur S; Fanti P; Szyndralewiez C; Barnes JL; Block K; Abboud HE
Am J Physiol Renal Physiol; 2015 Jun; 308(11):F1276-87. PubMed ID: 25656366
[TBL] [Abstract][Full Text] [Related]
16. Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice.
Menini S; Iacobini C; Ricci C; Blasetti Fantauzzi C; Pugliese G
Diabetologia; 2015 Apr; 58(4):845-53. PubMed ID: 25471794
[TBL] [Abstract][Full Text] [Related]
17. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lu Z; Zhang X; Li Y; Jin J; Huang Y
J Endocrinol; 2013 Jan; 216(1):61-71. PubMed ID: 23060524
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.
Aoyama T; Paik YH; Watanabe S; Laleu B; Gaggini F; Fioraso-Cartier L; Molango S; Heitz F; Merlot C; Szyndralewiez C; Page P; Brenner DA
Hepatology; 2012 Dec; 56(6):2316-27. PubMed ID: 22806357
[TBL] [Abstract][Full Text] [Related]
19. Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.
Gray SP; Jha JC; Kennedy K; van Bommel E; Chew P; Szyndralewiez C; Touyz RM; Schmidt HHHW; Cooper ME; Jandeleit-Dahm KAM
Diabetologia; 2017 May; 60(5):927-937. PubMed ID: 28160092
[TBL] [Abstract][Full Text] [Related]
20. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury.
Cha JJ; Min HS; Kim KT; Kim JE; Ghee JY; Kim HW; Lee JE; Han JY; Lee G; Ha HJ; Bae YS; Lee SR; Moon SH; Lee SC; Kim G; Kang YS; Cha DR
Lab Invest; 2017 Apr; 97(4):419-431. PubMed ID: 28165467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
